Eli Lilly recently announced a significant increase in its annual sales forecast due to explosive demand and increased manufacturing capacity for its weight-loss drug Zepbound. This development has driven the company’s shares to rise nearly 6% in value. The company expects to see substantial production increases in the second half of the year for its